ReviewTherapeutic advances in endocrinology and metabolism2019
Current best practice in the management of neuroendocrine tumors.
Review in Therapeutic advances in endocrinology and metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 78 citations in OpenAlex.
- Neuroendocrine tumors of unknown primary: a case report and review of tumors with gastroenteropancreatic features.Journal of gastrointestinal oncology · 2026Article
- A Twisted Tale: Ileocolic Intussusception in an Adult: A Case Report.Clinical case reports · 2026Article
- Neuroendocrine Neoplasms of the Gastrointestinal Tract: Morphology, WHO 2022 Grading, and Prognostic Perspectives.Cureus · 2026Review
- Posology for 177Lu-DOTATATE Therapy in Neuroendocrine Tumor: Effectiveness of Dose Reduction and Cycle Delay for Improving Therapy Tolerability.Clinical nuclear medicine · 2025Article
- Update in the Management of ACTH-Secreting Gastroenteropancreatic and Thoracic Neuroendocrine Neoplasms.Current treatment options in oncology · 2025Review
- Tumor-to-tumor metastasis: case report of a neuroendocrine tumor of the lung metastasizing to a benign oncocytoma of the kidney.The Canadian journal of urology · 2025Article
- Incidence trends and relative survival of colorectal neuroendocrine neoplasms: A population-based study using German cancer registry data.International journal of cancer · 2025Article
- Personal Health Record Software for Neuroendocrine Tumors: Patient-Centered Design Approach.JMIR human factors · 2025Article
- Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II study.EClinicalMedicine · 2025Article
- A Reassessment of the Clinical Utility ofJournal of surgical oncology · 2025Article
- Article
- Incidental Appendiceal Neuroendocrine Tumor Post Appendectomy: Surgery Is Here to Stay.Cureus · 2025Article
- A Rare Discovery of Neuroendocrine Tumor: Cardiac Mass.Journal of community hospital internal medicine perspectives · 2025Article
- A Challenging Decision: Identifying and Managing Hepatic Hydrothorax in the Setting of a Pancreatic Neuroendocrine Tumor.Case reports in gastrointestinal medicine · 2025Article
- Article
- A Neuroendocrine Tumor of Unknown Primary Origin: A Case Report and Review of the Literature.Cureus · 2024Article
- Octreotide plus IBI-318 plus anlotinib in the treatment of multiple neuroendocrine metastases of unknown primary lesions: a case report.Frontiers in oncology · 2024Article
- Predictors of Long-Term Outcomes After Liver Transplantation for Unresectable Metastatic Neuroendocrine Tumors.Annals of transplantation · 2023Article
- Neuroendocrine Tumor Metastases to the Breast: A Case Report and Review of the Literature.Cureus · 2023Article
- Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies.Cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine neoplasms are rare tumors that display marked heterogeneity with varying natural history, biological behavior, response to therapy and prognosis. Their management is complex, particularly as a number of them may be associated with a secretory syndrome and involve a variety of options. A number of factors such as proliferation rate, degree of differentiation, functionality and extent of the disease are mostly utilized to tailor treatment accordingly, ideally in the context of a multidisciplinary team. In addition, a number of relevant scientific societies have published therapeutic guidelines in an attempt to direct and promote evidence-based treatment. Surgery remains the treatment of choice with an intention to cure while it may also be recommended in some cases of metastatic disease and difficult to control secretory syndromes. Long-acting somatostatin analogs constitute the main treatment for the majority of functioning tumors, whereas specific evolving agents such as telotristat may be used for the control of carcinoid syndrome and related sequelae. In patients with advanced disease not amenable to surgical resection, treatment options include locoregional therapies, long-acting somatostatin analogs, molecular targeted agents, radionuclides, chemotherapy and recently immunotherapy, alone or in combination. However, the ideal time of treatment initiation, sequence of administration of different therapies and identification of robust prognostic markers to select the most appropriate treatment for each individual patient still need to be defined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.